Citius Pharmaceuticals Inc. (CTXR)
NASDAQ: CTXRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CTXR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $13.96M
- EPS (TTM)
- -$1.75
- Dividend yield
- None
- 52-week range
- 0.37 – 1.54
- Day range
- 0.4805 – 0.5136
- Volume / Avg
- 183.70K / 275.44K
- Beta
- —
- Shares outstanding
- 27.45M
- Next earnings
- Dec 22, 2026
52-week range
CTXR stock today
On Nov 20, CTXR ended the session at $0.5085, adding $0.0113 (2.27%), versus the S&P 500's 3.70% decline. Shares are 67.0% below their 52-week high of $1.54, set on Nov 26, 2025 and 37.4% above the 52-week low of $0.37, near the bottom of the past year's range. CTXR is down 34.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.4%.
Citius Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.75), so its P/E ratio is not meaningful. Citius Pharmaceuticals's next earnings report is expected on Dec 22, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Citius Pharmaceuticals
Company profileCitius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Leonard L. Mazur
- Headquarters
- Cranford, NJ
- Employees
- 23
- Website
- citiuspharma.com
Financial highlights
Full financialsCitius Pharmaceuticals reported a net loss of $39.7 million, compared with a loss of $39.4 million a year earlier. Diluted earnings per share came in at -$3.38.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $90.00K | $90.00K |
| Growth | — | — | — | 0.00% | 0.00% |
| Net income | $-39.74M | $-39.43M | $-32.54M | $-33.64M | $-23.05M |
| EPS (diluted) | $-3.38 | $-5.97 | $-5.57 | $-0.23 | $-0.23 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$4.00+686.63%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 22, 2026
- EPS estimate
- $-0.41
- Last reported (Q3 2026)
- Aug 14, 2026
- EPS actual vs est.
- $-0.34 vs —
CTXR news
All CTXR newsCitius Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BYSIBeyondSpring Inc. | 0.33 | -24.49% | $13.66M | vs CTXR |
| ACTUActuate Therapeutics Inc. | 0.2253 | +5.38% | $13.60M | vs CTXR |
| NCELNewcelX Ltd. | 2.54 | -5.58% | $14.67M | vs CTXR |
| TVRDTvardi Therapeutics Inc. | 0.9893 | +4.57% | $13.22M | vs CTXR |
| CNTXContext Therapeutics Inc. | 0.16 | -5.10% | $14.70M | vs CTXR |
| CELUCelularity Inc. Class A | 0.463 | -1.05% | $15.02M | vs CTXR |
| BOLTBolt Biotherapeutics Inc. | 4.91 | -2.96% | $12.80M | vs CTXR |
| NEUPNeuphoria Therapeutics Inc. | 2.35 | +1.29% | $12.72M | vs CTXR |
Indexes, lists and sector
Citius Pharmaceuticals stock FAQ
What is Citius Pharmaceuticals's stock price today?
CTXR last traded at $0.5085 as of Nov 20, 4:00 PM EST, up 2.27% on the day. Prices are delayed at least 15 minutes.
Does Citius Pharmaceuticals pay a dividend?
No. Citius Pharmaceuticals does not currently pay a regular cash dividend.
When is Citius Pharmaceuticals's next earnings date?
Citius Pharmaceuticals is expected to report earnings on Tuesday, December 22, 2026. Analysts expect EPS of $-0.41.
Who is Citius Pharmaceuticals's CEO?
Mr. Leonard L. Mazur is the chief executive officer of Citius Pharmaceuticals Inc., which has about 23 employees.
Has CTXR ever split its stock?
Yes. The most recent CTXR stock split was a 1-for-25 split on Nov 26, 2024, one of 2 splits on record.
What is the CTXR 52-week high?
The 52-week high for CTXR is $1.54 and the 52-week low is $0.37. The stock is currently 67.0% below its high.